intracoronary infusion of acetylcholine

Small molecule

AAzienda Ospedaliera San Camillo Forlanini

intracoronary infusion of acetylcholine is one of 42 small molecule programs targeting Endothelial Dysfunction. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endothelial DysfunctionActive, not recruiting

Endothelial DysfunctionPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

91 competitors in Endothelial Dysfunction

#DrugCompanyPhaseTrials

Avapro

Sanofi

Approved

2 2

Uloric

Takeda

Phase 3

2 3

Diamicron

Merck & Co.

Phase 3

1 4

Januvia

ZZydus Therapeutics Inc.

Phase 3

1 5

Inomax

MMallinckrodt

Phase 3

1 6

Glucophage

EMD Serono

Phase 3

1 7

Kremezin

Astellas

Approved

1 8

Kuvan

BioMarin Pharmaceutical

Phase 2

1 9

Tekturna

Tibotec Pharmaceuticals, Ireland

Phase 2

1 10

Aurlumyn

BBTG International Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endothelial Dysfunction1 trial

Comparison of Endothelial Dysfunction (BMS vs SES) in the Same Patient With Multiple Coronary Artery Lesions

Completed·AAzienda Ospedaliera San Camillo Forlanini·Phase 1/2·NCT01242306·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for intracoronary infusion of acetylcholine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intracoronary infusion of acetylcholine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intracoronary infusion of acetylcholine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azienda Ospedaliera San Camillo Forlanini company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AAzienda Ospedaliera San Camillo Forlanini

intracoronary infusion of acetylcholine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endothelial Dysfunction1 trial

References

Drug Info

Quick Facts

Related News